Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
C4 Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights Established Exclusive Licensing Agreement for CFT8919, an EGFR L858R BiDAC™ Degrader, with Betta Pharmaceuticals in Greater China for NSCLC&#59; U.S. IND Cleared"
05/04/2023 8-K Quarterly results
Docs: "C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights Preclinical Data Presented at AACR Demonstrated CFT1946 is a Potent and Mutant-Selective BRAF V600 BiDAC™ Degrader&#59; Phase 1/2 Clinical Trial Enrolling Patients"
02/23/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights Phase 1 Dose Escalation Data from the Ongoing Phase 1/2 Clinical Trials of CFT7455, an IKZF1/3 MonoDAC™ Degrader, and CFT8634, a BRD9 BiDAC™ Degrader, Expected in 2H 2023"
02/02/2023 8-K Quarterly results
01/09/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines Phase 1/2 Trial of CFT7455, an IKZF1/3 MonoDAC™ Degrader, Continues to Progress with Phase 1 Dose Escalation Data Expected in 2H 2023&#59; Enrollment Open for Arm Evaluating CFT7455 in Combination with Dexamethasone"
11/03/2022 8-K Quarterly results
Docs: "C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights"
08/04/2022 8-K Quarterly results
08/02/2022 8-K Quarterly results
06/24/2022 8-K Quarterly results
06/17/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
04/08/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "C4 Therapeutics Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical Trial of CFT7455, a Novel IKZF1/3 Degrader –",
"Corporate Presentation of the Company"
03/16/2022 8-K Quarterly results
02/24/2022 8-K Quarterly results
01/10/2022 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation Portfolio – Initial Phase 1 Data for CFT7455, a Novel IKZF1/3 Degrader, Expected in 1H 2022–"
11/30/2021 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Lease Amendment, by and between C4 Therapeutics, Inc. and Columbia Massachusetts Arsenal Office Properties, LLC"
11/10/2021 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "C4 Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results – Phase 1/2 study of CFT7455, a Novel IKZF1/3 Degrader, Progressing with Data Expected in 2022; Trial-in-Progress Poster Accepted for Presentation at 63rd ASH Annual Meeting –"
08/11/2021 8-K Quarterly results
06/21/2021 8-K Quarterly results
06/14/2021 8-K Other Events, Financial Statements and Exhibits
Docs: "C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT7455, An Orally Bioavailable MonoDAC for Hematologic Malignancies – CFT7455 is Company’s First Program to Advance to Clinic –",
"C4 Therapeutics Launches Proposed Public Offering"
06/07/2021 8-K Other Events, Financial Statements and Exhibits
Docs: "C4 Therapeutics Presents Pre-clinical Data on CFT8919, A Selective Degrader of EGFR L858R, at Keystone Symposium on Targeted Protein Degradation –",
"Corporate Presentation of the Company"
05/26/2021 8-K Investor presentation
Docs: "C4 Therapeutics to Advance CFT8919, A Selective Degrader of EGFR L858R, Into IND-enabling Studies – IND Submission for CFT8919 Anticipated mid-2022; Phase 1/2 Trial Initiation Expected by YE 2022 – –",
"Corporate Presentation of the Company (furnished herewith)"
05/20/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "C4 Therapeutics Appoints Lauren White as Chief Financial Officer"
05/13/2021 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "C4 Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results – Preclinical Data for CFT7455, a novel IKZF1/3 Degrader, in Non-Hodgkin's Lymphoma Xenograft Models Accepted for Presentation at the International Conference on Malignant Lymphoma in June –"
04/30/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/11/2021 8-K Quarterly results
01/12/2021 8-K Quarterly results
01/06/2021 8-K Regulation FD Disclosure
Docs: "C4 Therapeutics Announces Key 2021 Milestones to Support Progress Toward Goal of Four Clinical-Stage Programs by Year-End 2022 – Investigational New Drug Application for Lead Candidate CFT7455, a MonoDAC™ targeting IKZF1/3 for the Treatment of Hematologic Malignancies, Under FDA Review; Initiation of Phase 1/2 Trial Expected in 1H 2021 –"
11/19/2020 8-K Investor presentation
Docs: "Investor Presentation of the Company dated November 2020 (furnished herewith)"
11/12/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 12, 2020 C4 THERAPEUTICS, INC. Delaware 001-39567 47-5617627 490 Arsenal Way, Suite 200 Watertown, MA 02472 Registrant's Telephone Number, Including Area Code: 231-0700 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-...",
"C4 Therapeutics Reports Business Highlights and Third Quarter 2020 Financial Results"
10/06/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Fifth Amended and Restated Certificate of Incorporation of C4 Therapeutics, Inc"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy